Objectives: Gene-expression profiling (GEP) reliably supplements traditional clinicopathological information on the tissue of origin (TOO) in metastatic or poorly differentiated cancer. A cost-effectiveness analysis of GEP TOO testing versus usual care was conducted from a US third-party payer perspective. Methods: Data on recommendation changes for chemotherapy, surgery, radiation therapy, blood tests, imaging investigations, and hospice care were obtained from a retrospective, observational study of patients whose physicians received GEP TOO test results. The effects of chemotherapy recommendation changes on survival were based on the results of trials cited in National Comprehensive Cancer Network and UpToDate guidelines. Drug and administration costs were based on average doses reported in National Comprehensive Cancer Network guidelines. Other unit costs came from Centers for Medicare & Medicaid Services fee schedules. Quality-of-life weights were obtained from literature. Bootstrap analysis estimated sample variability; probabilistic sensitivity analysis addressed parameter uncertainty. Results: Chemotherapy regimen recommendations consistent with guidelines for final tumor-site diagnoses increased significantly from 42% to 65% (net difference 23%; P o 0.001). Projected overall survival increased from 15.9 to 19.5 months (mean difference 3.6 months; two-sided 95% confidence interval [CI] 3.2-3.9). The average increase in qualityadjusted life-months was 2.7 months (95% CI 1.5-4.3), and average third-party payer costs per patient increased by $10,360 (95% CI $2, 982-$19,192). The cost per quality-adjusted life-year gained was $46,858 (95% CI $13,351-$104,269). Conclusions: GEP TOO testing significantly altered clinical practice patterns and is projected to increase overall survival, quality-adjusted life-years, and costs, resulting in an expected cost per quality-adjusted life-year of less than $50,000.
Introduction
More than 30,000 cases of cancer of unknown primary (CUP) are diagnosed annually in the United States, representing 2% of all new cancer cases [1, 2] . In other cases, a leading diagnosis for the primary site has been made; however, substantial uncertainty about the tissue-site diagnosis still remains, especially when the cancer is metastatic, poorly differentiated, or undifferentiated. This can result in an exhaustive and costly ''diagnostic odyssey'' [3, 4] .
Current National Comprehensive Cancer Network (NCCN) guideline-recommended regimens for CUP consist of paclitaxel and carboplatin with or without etoposide, docetaxel and carboplatin, gemcitabine and cisplatin, or gemcitabine and docetaxel; median survival with these treatments is 6 to 9 months [5, 6] . Studies have shown that survival may be improved if cancerspecific therapy is targeted to the correct tumor type, demonstrating the need for effective and accurate identification of the tissue of origin (TOO) [5, 7, 8] .
The NCCN guideline-recommended evaluation of metastatic or poorly differentiated CUP includes a thorough history and physical examination (including breast, genitourinary, pelvic, and rectal examinations where appropriate), complete blood cell count, urinalysis, basic serum chemistries, chest radiograph, and computed tomography or magnetic resonance imaging of the abdomen and pelvis [5] . Immunohistochemistry (IHC) testing of the biopsy material is commonly used to characterize cellular differentiation and pathological diagnosis in poorly differentiated carcinomas [5] . Studies have recognized limitations-for example, with respect to consistency, reproducibility, sensitivity, specificity, and result interpretation or reporting-of conventional morphological evaluation and IHC testing, prompting a search for more reliable and accurate methods of identifying the primary site in poorly differentiated carcinomas [9] [10] [11] [12] .
The gene-expression profiling (GEP) TOO Test (Pathwork Diagnostics, Inc., Redwood City, CA) of biopsy material has been cleared by the US Food and Drug Administration and validated to provide independent information on the TOO [13] [14] [15] [16] . The processing laboratory has Clinical Laboratory Improvement Amendments certification. The GEP TOO test is a microarray, reagent, and analytics kit that uses a 2000-gene profile to quantify the similarity of tumor specimens to 15 cancer types representing 58 morphologies. GEP TOO test results provide similarity scores that range from 0 to 100 and indicate the most likely primary site from among a panel of 15 tissue types. The probability of obtaining a true positive tissue call with a similarity score of 30 or more is 92.9% (95% confidence interval [CI] 90.3-95.0), and the probability of obtaining a true negative tissue call with a similarity score of 5 or less is 99.7% (95% CI 99.6-99.8) [16] . In a clinical verification study, Dumur et al. [17] showed higher performance of the GEP TOO test to identify the correct tissue site compared with wellestablished immunohistochemical algorithms. In a subsequent clinical-utility study of 107 patients with CUP, physicians changed the primary tissue-site diagnosis in 50% of the patients (95% CI [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] and changed cancer-specific management in 65% of the patients (95% CI 58-73) [18] .
Although the long-term clinical and economic implications of GEP TOO testing are yet to be assessed, several studies have shown that adherence to guideline-recommended treatment may result in more cost-effective management of patients with cancer [19] [20] [21] . The specific aim of our study was to assess the cost-effectiveness of GEP TOO testing in the context of the current diagnostic paradigm and standard treatment regimens.
Methods

Analytical Framework
We performed a cost-effectiveness analysis from a US thirdparty payer perspective to assess the effect of GEP TOO testing on quality-adjusted life-years (QALYs) and direct medical costs over a patient's lifetime. We performed the analysis with an individual-sampling method by using data from a retrospective, observational study of patients whose physician had received the GEP TOO test results to help diagnose the tissue site of a patient's malignancy and guide appropriate therapy. The study included 107 patients whose physicians ordered and received a GEP TOO test result between July 2009 and December 2009. Patients were 18 years or older and had metastatic cancer in which the primary origin remained uncertain despite extensive clinical and pathological evaluation. The study documented changes in tumor-site diagnosis and cancer management recommendations before and after physicians received the GEP TOO test results. An institutional review board approved all aspects of the study (Quorum Review, Inc., Seattle, WA).
We defined usual care as cancer management decisions based on history and physical examination, imaging studies, selected blood tests, and pathology, including IHC ( Fig. 1 ). With usual care, the physician selected a treatment without the benefit of diagnostic information from the GEP TOO test.
Before and after receiving the GEP TOO test results, some physicians in the study recommended a chemotherapy regimen. We refer to chemotherapy regimens that included one or more agents recommended by clinical guidelines as guideline-consistent regimens (GCRs). We refer to regimens containing no agents recommended by clinical guidelines as non-GCRs. Two independent researchers determined whether to classify each chemotherapy regimen as a GCR or non-GCR on the basis of the regimens recommended in NCCN and UpToDate guidelines for metastatic and/or poorly differentiated cancers, and according to the physician's final tissue-site diagnosis [5, 22] . The two independent researchers reached the same conclusions about whether regimens were GCRs or non-GCRs for 207 of the 214 chemotherapy regimens recommended in this study; consensus was reached on 213 total cases. The uncertain regimen was a pre-GEP TOO treatment recommendation for gemcitabine and docetaxel in a patient with an initial diagnosis of CUP. After GEP TOO testing, the patient's diagnosis changed to soft tissue sarcoma and the chemotherapy treatment recommendation changed to doxorubicin and cisplatin. A third independent rater determined that the pre-GEP TOO chemotherapy recommendation was a GCR for soft tissue sarcoma and reviewed and confirmed the other six classifications on which the two other independent raters had initially disagreed.
We calculated the incremental cost per QALY gained as the ratio of the difference in lifetime costs of care and QALYs gained when physicians determined the final tissue-site diagnosis after obtaining GEP TOO test results versus before obtaining results, that is, ''usual care'' [23] . We computed QALYs as the product of quality-of-life (QOL) weights and literature-derived survival time. We report costs in 2011 US dollars. The model applied a standard annual discount rate of 3% for costs and benefits [23, 24] . The time horizon equaled the patient's lifetime [23] . Fig. 1 -1 Based only on history/physical examination, imaging studies, and pathology; 2 based on history/physical examination, imaging studies, pathology, and GEP TOO results; 3 whether CT is GCR versus non-GCR is based on physician's final reported tissue-site diagnosis after receiving GEP TOO results. GEP, gene-expression profiling; TOO, tissue of origin; CT, chemotherapy; GCR, guideline-consistent regimen; BSC, best-supportive care.
Effects of Management Changes on Overall Survival and QALYs
We reviewed the medical literature to document median overall survival associated with chemotherapy regimens for specific tumor types, relying primarily on estimates from controlled trials or meta-analyses of controlled trials cited in UpToDate or NCCN guidelines [5, 22] . We abstracted studies initially for information on patient survival when patients with metastatic tumors had received no chemotherapy regimen; in most instances, these estimates reflected the survival of patients in a placebo-control arm of a trial. For studies of GCRs, we abstracted estimates of the median overall survival from published studies. Estimates of the survival effects of chemotherapy regimens that are not recommended in guidelines for a tissue type were often unavailable in the literature. In the base case, we assumed that non-GCRs not provided in the literature had the same effect on survival as those found in the literature and we varied the effect on survival between 0% (no survival benefit over best supportive care) and 100% (same benefit as GCRs). The survival benefit associated with GCR versus non-GCR varies by tissue type ( Table 1) . For example, no benefit has been reported for patients with neuroendocrine pancreatic cancer. The maximum benefit between GCR and non-GCR is 24 months, reported for ovarian cancer.
We conservatively assumed that changes in surgery and radiation therapy associated with receiving GEP TOO test results had no effect on overall survival; this assumption biases the analyses against GEP TOO testing. Early referral to hospice care has been shown to increase the overall survival by approximately 2.7 months; we therefore ascribed a 2.7-month survival benefit for patients referred to hospice [101, 102] . Some patients who were referred to hospice after GEP TOO testing also received chemotherapy, presumably for palliative purposes. We set the effect of these management changes on overall survival to be equal to the maximum of the effect from either the recommended chemotherapy or hospice care, but not both. We obtained de-identified social security data on whether each patient had died and the date of death. We used these data to calculate the duration of survival from the time that physicians received the test results.
We assigned QOL weights on the basis of the classification of the chemotherapy regimen (no chemotherapy, non-GCR, or GCR). We searched the online Tufts Cost-Effectiveness Analysis Registry database and PubMed for evidence on QOL weights for metastatic cancer and the effect of chemotherapy on response and chemotherapy-related adverse events [101, 102] . We limited the search to controlled trials and used ''metastatic'' and the names of standardized health outcome instruments (''EuroQol'' or ''EQ-5D'') as search terms. QOL weights associated with metastatic cancer were highly variable across studies, ranging from 0.15 to 0.8. In a study of metastatic renal cell carcinoma, the initial best supportive care QOL weight was 0.5509, which increased to 0.7153 for non-GCR (interferon-a) chemotherapy and to 0.7599 with use of a targeted chemotherapy regimen (sunitinib) that is consistent with NCCN guidelines [103] . For adverse events and/or inconvenience related to the chemotherapy regimen, we added a 0.0386 decrement (or tariff) in QOL, multiplied by an average of 4 months of receiving a chemotherapy regimen [103] . Because studies have not reported QOL weights associated with referrals to hospice care, we ascribed no change in QOL to referrals to hospice care. We also ascribed no changes in QOL to reductions in patient uncertainty about their tissue-site diagnosis and management plans [104] . Omitting QOL effects for hospice and uncertainty of diagnosis probably biased the analysis against GEP TOO testing. We also ascribed no QOL change to the use of radiation therapy because of a lack of published data. The effects of radiation therapy on QOL are complex because QOL might decline because of radiation-related adverse effects, but it might also increase as a result of tumor debulking and symptom management. Presumably, physicians and patients considered these trade-offs, and so the benefits of tumor debulking and symptom management outweighed the risk of adverse effects.
Costs
We estimated third-party costs per patient for all chemotherapy regimens, radiation therapies, surgeries, hospice care, further investigations, and IHCs prescribed for each patient. The GEP TOO test kit's cost used for these analyses was the list price of $4400. We assumed that GEP TOO testing would not affect surgeries for diagnosis, staging, and debulking that had been performed before physicians received the test results. We included only new investigations arising from the GEP TOO test results in the analyses. We derived unit drug costs from Centers for Medicare & Medicaid Services (CMS) fee schedules, and we based dosages on NCCN guidelines, package inserts, UpToDate.com, and OVID Clin-eguide TM [18, 22, 105, 106] . We derived drug administration costs from the number of hours to infuse agents and the CMS reimbursement associated with outpatient infusion Current Procedural Terminology codes [105] . We applied CMS Medicare Severity Diagnosis-Related Group weights to calculate the costs of surgeries and radiation therapy [106] and CMS fee schedules for costs of IHCs (HCPC 88342) [107] . We searched the literature for the percentage change in thirdparty payer costs associated with referrals to hospice care [19, [108] [109] [110] . Studies reported a mean reduction of between 11% and 79% in third-party payer costs for each referral to hospice care. The average reduction in third-party payer costs for hospice care referrals, weighted by study size, was 46%, which amounted to a $6520 savings for hospice care referrals that we included in the model. We omitted costs related to outpatient visits because patients in the target population are seen frequently for surveillance purposes, and GEP TOO testing is unlikely to alter these patterns of care significantly. We hypothesized that the administration of more effective chemotherapy regimens delays disease progression and thereby reduce morbidity. Our model conservatively omitted these costs, and so only the immediate effects of GEP TOO testing on changes in clinical practice, medical resource use, and thus third-party payer costs are considered.
Data Analysis and Sensitivity Analysis
The primary end points for our data analysis were (1) mean change in overall survival, (2) mean change in QALYs, (3) mean change in total cancer-related costs, and (4) cost per QALY gained before and after GEP TOO testing. We summarized study variables by using descriptive statistics: sample means, medians, SDs, minimums, and maximums. We converted overall survival medians from the literature to means for the QALY analysis by modeling survival with constant hazard ratios, which showed median survival to be 70% of mean survival. We used a two-sided bootstrap t test at a 0.05 level of significance to assess the effect of sample variance on differences in end points before and after GEP TOO testing [111, 112] .
We conducted a one-way sensitivity analysis, a two-way sensitivity analysis, and a probabilistic sensitivity analysis on the model parameters by using a second-order Monte Carlo simulation (computational algorithm based on repeated random sampling). We estimated the sample variance in QALYs by using bootstrap techniques; we assessed 95% CIs in QALYs and cost per QALY due to parameter uncertainty, such as utilities, in the probabilistic sensitivity analysis. We introduced the variable ''relative effect of GEP TOO testing'' to address the limitations of an observational design. In sensitivity analyses, this variable modified the relative effect of GEP TOO testing from the observed effects seen in the study. Table 2 shows the input parameters and distributions used in the model.
Results
The characteristics of patients in the study are shown in Table 3 ; further details are given in Appendix Table 1 found at doi: 10.1016/j.jval.2010.10.016. Sixty-one (57%) patients were women. The mean patient age was 64Ϯ12 years; 54 (50%) patients were 65 years or older. Reported race/ethnicity was white for 89% of the patients. Of the 91 patients with a reported Easter Cooperative Oncology Group score, 87 (81%) had a score of 2 or less. A total of 19 biopsy sites were reported in the tissue samples submitted for GEP TOO testing. The six most common biopsy sites, each with at least five reported cases, were lymph node (21%), soft tissue (20%), liver (18%), lung (9%), bone (7%), and brain (5%). The most common diagnoses after GEP TOO testing, each with at least nine reported cases, were lung (13%), colorectal (11%), pancreas (9%), and ovarian (8%) cancer. Table 1 shows the median overall survival by tissue-type diagnosis and chemotherapy regimen. With best supportive care involving no chemotherapy, the median overall survival across all tissue-type diagnosis is projected to be 6.2 months (range 1-44 months). Median overall survival using a non-GCR regimen (i.e., a regimen that is not guideline consistent for the final tissue-type diagnosis) increases to 8.9 months (range 4.9 to at least 49 months). Median overall survival using a GCR regimen that is specific for the final tissue-type diagnosis increases to 15.9 months (range 6.6 to at least 120 months). Patients with metastatic cancers such as breast, colorectal, kidney, ovarian, and pancreatobiliary survive substantially longer after undergoing GCR than after non-GCR. In contrast, studies showed that patients with anal, cervical, gastric, and uterine metastatic cancers would receive only a small or insignificant benefit from GCR. Based on the regimen recommended before GEP TOO testing, the median overall survival is estimated to be 11.1 months (range 1 to at least 49 months).
GEP TOO testing resulted in a significant change in recommended chemotherapy regimens (Table 4 ). Before having information from GEP TOO testing, physicians recommended GCRs for 42% of the patients and non-GCRs for 28% of the patients.
Physicians recommended no chemotherapy for 30% of the patients before obtaining GEP TOO test results. With the additional information from GEP TOO testing, physicians recommended a GCR for 23% more patients, an increase from 42% to 65% of the patients, and they recommended a non-GCR for 15% fewer patients, a decline from 28% to 13%. GEP TOO testing also increased the proportion of patients whose physicians recommended chemotherapy from 70% to 79%. Other aspects of cancer management that changed after GEP TOO testing were that physicians recommended additional investigations (blood tests or imaging) for 18 (17%) patients, referring 14 patients to hospice immediately after receiving GEP TOO test results, recommending radiation therapy for 19 fewer patients and additional surgery for 5 patients.
The median overall survival projected for patients after GCR was 13.6 (range 6.6 to at least 49 months) ( Table 1 ). The actual median overall survival for the 107 patients in the cohort was 14.0 months (95% CI 10.2-18.6) (Appendix Figure 1 found at 19, 192) . We estimated the incremental cost-effectiveness ratio (ICER) to be $46,858 (95% CI $13,351-$104,269) ( Table 5) .
By considering parameter uncertainty and sample variance in the probabilistic sensitivity analysis, the 2.5th and 97.5th percentiles of QALYs were 0.125 and 0.360, respectively; the 2.5th and 97.5th percentiles of the ICER were $13,351 and $104,269, respectively ( Fig. 2; Table 2 ). A one-way sensitivity analysis showed utility of GCRs, chemotherapy costs with GEP TOO testing, and sample variance of quality-adjusted life-months to be the key drivers of GEP TOO test's cost-effectiveness ( Fig. 3) . Figure 4 shows the results of a two-way sensitivity analysis that we performed by simultaneously varying the imputed effect of non-GCR regimens on survival and the relative effect of GEP TOO testing, the two variables for which no registry study or literature data were available. The two-way sensitivity analysis demonstrated that the ICER was more sensitive to the relative effect of GEP TOO testing than to the imputed effect of non-GCR regimens. The ICER increased by 39% (to $65,134) when the relative effect of GEP TOO testing decreased by 50% and no effect of non-GCR regimens was considered. The ICER decreased by approximately 12% (to $41,095) when the relative effect of GEP TOO testing increased by 50% and the effect of non-GCR regimens on survival was assumed to be 100%. Eliminating the one case for Note. Pearson chi-square ¼ 28.6; P o 0.001. BSC, best supportive care; CT, chemotherapy; GCR, guideline-consistent regimen; GEP, gene-expression profiling; TOO, tissue of origin. which GCR/non-GCR classification differed among independent raters decreased the ICER by 1%, to $46,248.
Discussion
This study is the first to estimate the outcomes, costs, and costeffectiveness of a novel GEP test, GEP TOO, versus usual care among patients with metastatic and poorly differentiated cancer. Patients in this sample had characteristics similar to those of patients enrolled in other studies who have had metastatic cancer in which the primary origin remained uncertain despite extensive clinical and pathological evaluation [8, 15, 16] . Our study found that overall survival is likely to increase from 15.9 to 19.5 months with the use of GEP TOO testing. These survival estimates are consistent with the mean patient survival (20 months) from registry data for the patients in our study. We projected average costs per patient to increase, largely owing to physician plans to administer more GCRs, which are more costly than no chemotherapy or carboplatin plus paclitaxel (combined, these account for 54% of the pre-GEP TOO testing regimens). The test saves some costs by increasing referrals to hospice care and reducing the use of radiation therapy.
The duration and quality of patient survival increase substantially if a physician chooses a chemotherapy regimen that appropriately targets the correct tumor type [5, 7, 8] . This study showed that physicians ordered GCRs for an additional 1 in 4 patients after receiving GEP TOO test results, which is associated with improvements in patient QALYs. Literature showed the benefit of appropriate chemotherapy to differ substantially by cancer type. This difference is likely due to the variability in treatment advances made for these cancers. Sensitivity analyses showed that the effect of imputing survival for non-GCRs was minimal. The small number of cases for which survival had to be imputed likely accounts for this result.
The findings from this study should be evaluated in light of potential limitations. The study design for evaluating a new technology should limit risks to internal and external validity. A randomized controlled trial involving multiple centers that has a sufficiently large sample size is the strongest design for limiting risks to internal validity because it balances confounding variables among the comparator arms. For a number of pragmatic reasons, randomized studies are exceedingly rare in metastatic or poorly differentiated cancers that are more difficult to diagnose than other cancers. Funders, including government agencies, are reluctant to sponsor randomized trials of such cancers owing to the high costs associated with the extremely large sample sizes needed to achieve statistically significant results because of the heterogeneity in tumor and histological types and in treatment options for each tumor. Moreover, the lower incidence of some metastatic or poorly differentiated cancer presentations (such as cervical, parotid gland, and urethral) than that of other cancers (such as breast, lung, and colon), combined with historical challenges of recruiting patients into randomized trials in general, makes undertaking a randomized trial of GEP TOO testing difficult. Our approach relied on an established alternative, namely, an observational design that offers less confidence that risks to internal validity have been minimized. To address this concern, we varied the relative effect of GEP TOO testing on end points between 50% and 150% of the effect observed in the study. This approach offers the reader a transparent and explicit way to assess the effect of potential threats to the study's internal validity.
Another potential limitation is our omission of some potential effects on costs, such as potential savings from delaying costly progression and use of second-line therapies, and on QOL, such as reduced patient uncertainty about their diagnosis, increased confidence in the value of the recommended therapies, and QOL benefits from hospice referrals or radiation therapy. GEP TOO test results likely increased the QOL by increasing patient certainty, as indicated by physicians' belief that GEP TOO test results helped reduce patient anxiety about their diagnosis and the management of their cancer. Studies have shown that patients express willingness to pay for tests that reduce uncertainty in diagnosis even if the information may not alter therapy or outcomes [104] . Our omission of the effects of GEP TOO testing on these costs and QOL factors likely biased the cost-per-QALY estimate against GEP TOO testing. A longitudinal follow-up study would be useful for revealing the effect of GEP TOO testing on cancer progression and use of subsequent therapies and, thus, on costs and patient QOL. As the use of GEP TOO testing increases, studies with larger sample sizes will become possible. These studies will allow for a better understanding of the test's potential effects on radiation therapy and surgery. Such studies would also allow the use of statistical methods for causal inference [113] .
GEP TOO testing will probably be used for a small proportion ($2%) of the more than 1.5 million people who are likely to be diagnosed with cancer in 2012. A similar number of patients is likely to be eligible for the treatment of metastatic prostate cancer with the new drug sipuleucel-T (Provenge, Dendreon, Seattle, WA), which is estimated to cost more than $90,000 for a course of therapy to extend survival in the last year of life by about 4 months [104, 114] . The cost-effectiveness of the drug for this indication is likely to far exceed $100,000 per QALY saved.
Historically, $50,000 has been used as the threshold for costeffectiveness; however, assessments of current cancer management and dialysis strategies have shown more than $100,000 to be a more contemporary threshold for the adoption of health care technologies [115, 116] . We found that the cost per QALY gained with GEP TOO testing remained within both historical and contemporary thresholds. The cost per QALY gained would exceed $100,000 if the changes attributed to GEP TOO testing were less than 25% of those observed in this study.
GEP TOO testing significantly altered clinical practice patterns. We project that these changes increase overall survival and QALYs for patients whose physicians order the test. The estimated cost per QALY gained is less than $50,000, suggesting that GEP TOO testing is a cost-effective supplement for cancer management in patients with difficult-to-diagnose metastatic cancer. 
